Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations

Early dose-escalation data from Phase…Read More

You might also be interested in reading SoundThinking outlines $111M–$113M 2025 revenue target while advancing AI and critical infrastructure solutions.